- By Ambry Genetics
- Posted August 4, 2020
Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Breast Cancer
Ambry Genetics and the Mayo Clinic recently collaborated on the publication of “The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer from a Clinical Genetic Testing Cohort” in JNCI: The Journal of the National Cancer Institute (April 2020). Interested in hearing about the study from one…
- By Alice Lam
- Posted July 22, 2020
Hereditary Cancer Testing Menu Update
NOW AVAILABLE FOR ORDERS ON/AFTER JULY 22ND We are refreshing our hereditary cancer test menu based on the latest medical management guidelines, clinical literature, and customer feedback to deliver the most up-to-date, clinically relevant testing options to healthcare providers and patients. Contact your regional Account Executive or Genomic…
- By Mary Pritzlaff, MS, CGC
- Posted June 15, 2020
Study Finds Key Predictors of Positive Genetic Test Results in Men with Prostate Cancer
Genetic testing can identify men with prostate cancer who have pathogenic variants in genes associated with hereditary cancer. Results of genetic testing may be useful to inform treatment and management, identify men who are at greater risk for aggressive prostate cancer, and provide information about increased risks for other cancers for both…
- By Ambry Genetics
- Posted May 1, 2020
Ambry Genetics Virtual Booth ACMG 2020
Thank you for stopping by! Below you will find information on our research that was accepted by ACMG, along with some new and exciting things happening at Ambry. We hope that you are staying safe and healthy. Research Posters: 1) Genetic Testing Utilization Management: Saving Time, Saving Money, And Maximizing Clinical Utility For Patients-…
- By Tyler Landrith, PhD
- Posted March 5, 2020
Study Published in Nature Partner Journal Precision Oncology Confirms Clinical Utility of Simultaneous RNA and DNA Genetic Testing
DNA-based multigene panel testing (MGPT) is a commonly used approach for the detection of patients with or at-risk for inherited cancers. Despite years of advancement in genetic testing, patients may still receive uncertain results or receive a negative result despite having a personal or family history suggestive of hereditary cancer. RNA genetic…
- By Andy Castro
- Posted February 25, 2020
When Moments Matter, ExomeNext-Rapid Finds Answers
Quite often there is the connotation that Diagnostic Exome Sequencing (DES) is too slow, examines too many genes, is too expensive, and has limited clinical utility. Ambry Genetics counters those thoughts about DES with our ExomeNext-Rapid test (Test Code: 9999R). Ambry’s recent, peer-reviewed publication demonstrates how Rapid Diagnostic Exome…
- By Holly LaDuca, MS, CGC
- Posted January 7, 2020
Study Demonstrates that RNA Genetic Testing Reduces Inconclusive Results Providing More Clarity to Patients and Healthcare Providers
Genetic testing plays a critical role in the delivery of personalized medicine. Take, for instance, hereditary cancer, where genetic testing can help inform treatment and other management decisions for both individuals with an active cancer diagnosis and those at an increased risk for cancer. For the latter, genetic testing helps minimize their…
- By Marcy Richardson, PhD
- Posted September 10, 2019
3 Ways RNA Analysis will Change the Future of Genetic Testing
When it comes to medical questions, sometimes “unknown” is the worst answer you can receive. Uncertainty prevents a family from developing an action plan to combat bad news, or from achieving peace of mind when receiving good news. Yet for many patients who undergo genetic testing due to a suspected hereditary cancer syndrome, they are left…
- By Ambry Genetics
- Posted May 15, 2019
Familial Hypercholesterolemia: A Silent Threat That is too Often Missed
Familial hypercholesterolemia (FH) is an inherited genetic disorder characterized by markedly elevated low-density lipoprotein cholesterol (LDL-C) and accelerated atherosclerotic cardiovascular disease (ASCVD), leading to early heart attacks and heart disease. One of the most common genetic disorders, FH affects 1 in 250 individuals in the United…
- By Jessica Profato, MS, CGC
- Posted May 7, 2019
RNA Genetic Testing Brings Clarity to Lynch Syndrome Patients
MSH2 is one of five genes associated with Lynch syndrome, a condition that leaves patients with a significantly increased risk for colorectal and certain other cancers. Using genetic testing to identify patients with Lynch syndrome is important because they can be recommended increased cancer screenings for early detection and prevention.…